NUVL (Nuvalent) Payments of Debt : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nuvalent Payments of Debt?

Nuvalent's Payments of Debt for the three months ended in Sep. 2024 was $0.00 Mil.

Nuvalent's Payments of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Nuvalent Payments of Debt Historical Data

The historical data trend for Nuvalent's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvalent Payments of Debt Chart

Nuvalent Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Payments of Debt

-0.25

Nuvalent Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Payments of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Nuvalent Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Nuvalent Payments of Debt Related Terms

Thank you for viewing the detailed overview of Nuvalent's Payments of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvalent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvalent Inc (NAS:NUVL) » Definitions » Payments of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Broadway, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.nuvalent.com

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Executives

Alexandra Balcom	officer: Chief Financial Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Matthew Shair	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
James Richard Porter	director, officer: President and CEO	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Darlene Noci	officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
James E Flynn	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deborah Ann Miller	officer: Chief Legal Officer	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Emily Conley	director	C/O NUVALENT, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02142
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher Durant Turner	officer: Chief Medical Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Deerfield Mgmt L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p.	director, 10 percent owner, other: Director by Deputization	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michael L. Meyers	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Robert Bowers Jackson	director	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142